We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Name | Symbol | Market | Type |
---|---|---|---|
Quoin Pharmaceuticals Ltd | NASDAQ:QNRX | NASDAQ | Depository Receipt |
Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.0007 | 0.09% | 0.7658 | 0.7529 | 0.7658 | 0.79 | 0.7505 | 0.7536 | 17,090 | 17:42:32 |
| | | | | 1 | | | |
| | | | | 2 | | | |
| | | | | 6 | | | |
| | | | | 10 | | | |
| | | | | 12 | | |
Name and Address of Beneficial Owner
|
| |
Amount and
Nature of Beneficial Ownership |
| |
Percentage
of Class |
| ||||||
5% Beneficial Owners: | | | | | | | | | | | | | |
Lind Global Fund II LP(1)
|
| | | | 62,500 | | | | | | 6.3% | | |
Directors and Named Executive Officers: | | | | | | | | | | | | | |
Dr. Michael Myers(2)
|
| | | | 12,930 | | | | | | 1.3% | | |
Denise Carter(3)
|
| | | | 12,929 | | | | | | 1.3% | | |
Joseph Cooper(4)
|
| | | | 715 | | | | | | * | | |
James Culverwell(5)
|
| | | | 1,032 | | | | | | * | | |
Dr. Dennis Langer(6)
|
| | | | 1,065 | | | | | | * | | |
Natalie Leong(7)
|
| | | | 715 | | | | | | * | | |
Michael Sember(8)
|
| | | | 715 | | | | | | * | | |
Gordon Dunn(9)
|
| | | | 2,977 | | | | | | * | | |
All directors and officers as a group (8 persons)(10)
|
| | | | 33,075 | | | | | | 3.3% | | |
| | | | | | For | | | | Against | | | | Abstain | | |
| | To approve the issuance of the maximum number of the Company’s ordinary shares represented by ADSs issuable pursuant to the purchase agreement, dated as of January 25, 2024, with Alumni Capital LP (the “Alumni Issuance Proposal”). | | | | | | | | | | | | | | |
|
Name
|
| |
Signature
|
| |
Date
|
| | , 2024 | |
|
Name
|
| |
Signature
|
| |
Date
|
| | , 2024 | |
1 Year Quoin Pharmaceuticals Chart |
1 Month Quoin Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions